Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Radiotherapy Concurrent With PARP Inhibitor + Temozolomide Combined With Immune Checkpoint Inhibitor on SCLC After Initial Treatment Failure

NCT04790955 is registered in ClinicalTrials.gov with First Affiliated Hospital of Harbin Medical University as lead sponsor.

NCT NCT04790955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04790955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Radiotherapy Concurrent With PARP Inhibitor + Temozolomide Combined With Immune Checkpoint Inhibitor on SCLC After Initial Treatment Failure
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2021
Completion date
March 1, 2024
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer